<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/27E41B4B-AD07-4D59-BECA-D839DFC109C3"><gtr:id>27E41B4B-AD07-4D59-BECA-D839DFC109C3</gtr:id><gtr:name>Phico Therapeutics Limited</gtr:name><gtr:address><gtr:line1>Bertarelli Building Bourn Hall,High Street</gtr:line1><gtr:city>Bourn</gtr:city><gtr:postCode>CB23 2TN</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/27E41B4B-AD07-4D59-BECA-D839DFC109C3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>27E41B4B-AD07-4D59-BECA-D839DFC109C3</gtr:id><gtr:name>Phico Therapeutics Limited</gtr:name><gtr:address><gtr:line1>Bertarelli Building Bourn Hall,High Street</gtr:line1><gtr:city>Bourn</gtr:city><gtr:postCode>CB23 2TN</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>20000.0</gtr:offerGrant><gtr:projectCost>34610.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/55B0066D-A86D-499E-952F-762EFA313517"><gtr:id>55B0066D-A86D-499E-952F-762EFA313517</gtr:id><gtr:firstName>Heather</gtr:firstName><gtr:surname>Fairhead</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=700192"><gtr:id>4C8FA379-4B57-4B90-BAFD-F3528C898938</gtr:id><gtr:title>Phico Therapeutics Limited: Analysis of the product opportunities for a novel anti-bacterial platform technology</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Proof of Market</gtr:grantCategory><gtr:grantReference>700192</gtr:grantReference><gtr:abstractText>Antibiotic resistance is a global healthcare crisis. There are now bacteria which are resistant to
every marketed antibiotic and these are spreading around the world (HPA, 2011). The World
Health Organisation?s World Health Day in 2011 ?Antibiotic resistance ? no action today no
cure tomorrow? shows development of novel antibiotics that can treat resistant bacteria is
desperately needed.
Phico Therapeutics has developed a novel antibiotic technology called SASPject, which has
the potential to treat any bacterial infection including those caused by the most antibiotic
resistant bacteria. SASPject?s active ingredient, SASP, works in a way that means bacteria
cannot become immune. The technology also has the unique, characteristic of limiting the
spread of existing antibiotic resistance. Hence it could address the urgent medical need for
novel treatments against multi-drug resistant bacteria.
SASPject technology targets harmful bacteria selectively. For example, Phico has taken its
first product, targeted against MRSA for nasal use, successfully through a phase I clinical trial
demonstrating a good safety profile. Phico now plans to develop products for systemic use
targeted to those multi-drug resistant bacteria responsible for some of the most serious and life
threatening infections.
This SMART project will underpin Phico?s strategic development by producing a detailed and
in depth analysis of the markets for various possible SASPject products. This will allow
prioritisation of product development and clinical trial design.
Phico Therapeutics is a young biotechnology company with a novel and powerful
antibacterial platform technology. Based at Babraham Research Campus, it employs 16 staff,
including 9 post-doctoral scientists.
The project outcomes will also support a significant round of investment raising in 2013 to
enable Phico to take further anti-bacterial products through early clinical trials and ultimately,
via pharmaceutical partnerships, to market.</gtr:abstractText><gtr:fund><gtr:end>2013-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2012-12-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>20000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">700192</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>